Role of ROS1 fusion gene mutations in diagnosis and treatment of non-small cell lung cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 257-262, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-754408
ABSTRACT
The incidence of ROS1 gene rearrangement/fusion in non-small cell lung cancer (NSCLC) is about 1%-2%. The advent of tar-geted drugs for ROS1 gene fusion has significantly improved the quality of life and total survival of NSCLC patients with ROS1 fusion;however, acquired drug resistance is still present in most patients after continuous treatment. This review has summarized the back-ground of the ROS1 fusion gene, detection method, clinical efficacy of ROS1-targeted therapy, and strategy and prospect of drug resis-tance.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Diagnostic study
Language:
Chinese
Journal:
Chinese Journal of Clinical Oncology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS